All AbMole products are for research use only, cannot be used for human consumption.
LY2874455 is a novel and potent FGF/FGFR inhibitor. LY2874455 exhibits a potent activity against FGF/FGFR-mediated signaling in several cancer cell lines. LY2874455 exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice. LY2874455 did not show VEGF receptor 2-mediated toxicities such as hypertension at efficacious doses. Currently, this molecule is being evaluated for its potential use in the clinic.
| Cell Experiment | |
|---|---|
| Cell lines | KMS-11, OPM-2, L-363, U266, SNU-16, KATO-III, NUGC-3 and SH-10-TC cells |
| Preparation method | Growing cells (2,000 per well) first in RPMI for 6 hours and treating with LY2874455 at 37 ℃ for 3 days. Staining the cells at 37℃ for 4 hours and then solubilizing at 37℃ for 1 hour. Finally, using a plate reader (Spectra Max Gemini XS) to read the plate at 570 nm. |
| Concentrations | ~1 μM |
| Incubation time | 72 hours |
| Animal Experiment | |
|---|---|
| Animal models | Mice bearing RT-112, OPM-2 (DSMZ), SNU-16, or NCI-H460 xenograft |
| Formulation | 10% Acacia |
| Dosages | 3 mg/kg |
| Administration | p.o. |
| Molecular Weight | 444.31 |
| Formula | C21H19Cl2N5O2 |
| CAS Number | 1254473-64-7 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related FGFR Products |
|---|
| AZD4547
AZD4547 (Fexagratinib) is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
| BGJ398 (Infigratinib)
BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| PD173074
PD173074 is a selective FGFR1 and FGFR3 inhibitor with IC50 values of 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively. |
| SSR128129E
SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs. |
| SKLB610
SKLB610 is a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
